RU2003100502A - COMBINATIONS AND COMPOSITIONS THAT HAVE EFFECT ON THE FUNCTION OF VEGF SYSTEMS / VEGF RECEPTOR AND ANGIOPOETIN / TIE (II) RECEPTOR, AND THEIR APPLICATION - Google Patents
COMBINATIONS AND COMPOSITIONS THAT HAVE EFFECT ON THE FUNCTION OF VEGF SYSTEMS / VEGF RECEPTOR AND ANGIOPOETIN / TIE (II) RECEPTOR, AND THEIR APPLICATIONInfo
- Publication number
- RU2003100502A RU2003100502A RU2003100502/15A RU2003100502A RU2003100502A RU 2003100502 A RU2003100502 A RU 2003100502A RU 2003100502/15 A RU2003100502/15 A RU 2003100502/15A RU 2003100502 A RU2003100502 A RU 2003100502A RU 2003100502 A RU2003100502 A RU 2003100502A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- vegf
- pharmaceutical compositions
- agents
- systems
- Prior art date
Links
- 108091007928 VEGF receptors Proteins 0.000 title claims 13
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title claims 13
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 title claims 11
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 title claims 11
- 102000005962 receptors Human genes 0.000 title claims 8
- 108020003175 receptors Proteins 0.000 title claims 8
- 230000000694 effects Effects 0.000 title claims 3
- 239000000203 mixture Substances 0.000 title 2
- 150000001875 compounds Chemical class 0.000 claims 43
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 230000027455 binding Effects 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 210000003038 Endothelium Anatomy 0.000 claims 11
- 108010006830 TIE receptors Proteins 0.000 claims 11
- 102000005450 TIE receptors Human genes 0.000 claims 11
- -1 N, N-disubstituted carbamoyl Chemical group 0.000 claims 8
- 239000003446 ligand Substances 0.000 claims 8
- 230000000051 modifying Effects 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- YCOYDOIWSSHVCK-UHFFFAOYSA-O N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine;hydron Chemical compound C1=CC(Cl)=CC=C1[NH2+]C(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 YCOYDOIWSSHVCK-UHFFFAOYSA-O 0.000 claims 4
- 102000015636 Oligopeptides Human genes 0.000 claims 4
- 108010038807 Oligopeptides Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 102000004965 antibodies Human genes 0.000 claims 4
- 108090001123 antibodies Proteins 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 239000002502 liposome Substances 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000011780 sodium chloride Substances 0.000 claims 3
- 206010059512 Apoptosis Diseases 0.000 claims 2
- 102100016102 NTRK1 Human genes 0.000 claims 2
- 101700043017 NTRK1 Proteins 0.000 claims 2
- 229920000272 Oligonucleotide Polymers 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 125000004450 alkenylene group Chemical group 0.000 claims 2
- 125000002947 alkylene group Chemical group 0.000 claims 2
- 125000003277 amino group Chemical group 0.000 claims 2
- 230000006907 apoptotic process Effects 0.000 claims 2
- 125000004429 atoms Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 230000009089 cytolysis Effects 0.000 claims 2
- 239000002254 cytotoxic agent Substances 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 125000001841 imino group Chemical group [H]N=* 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000031146 intracellular signal transduction Effects 0.000 claims 2
- 230000017074 necrotic cell death Effects 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 125000004430 oxygen atoms Chemical group O* 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- 208000003120 Angiofibroma Diseases 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 206010003246 Arthritis Diseases 0.000 claims 1
- 206010003445 Ascites Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathy Diseases 0.000 claims 1
- 206010061835 Diabetic nephropathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000009745 Eye Disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 210000003734 Kidney Anatomy 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000003584 Mesangial Cells Anatomy 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 210000000944 Nerve Tissue Anatomy 0.000 claims 1
- 206010030113 Oedema Diseases 0.000 claims 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 201000001320 atherosclerosis Diseases 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 125000001246 bromo group Chemical group Br* 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 1
- 125000001589 carboacyl group Chemical group 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003176 fibrotic Effects 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 1
- 201000011066 hemangioma Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000004044 liver cirrhosis Diseases 0.000 claims 1
- 230000003211 malignant Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000003142 neovascular glaucoma Diseases 0.000 claims 1
- 201000009925 nephrosclerosis Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims 1
- 229920000728 polyester Polymers 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 201000004681 psoriasis Diseases 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000547 substituted alkyl group Chemical group 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000004434 sulfur atoms Chemical group 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
- 201000010874 syndrome Diseases 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 230000001732 thrombotic Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 Cc1c(*)c(*)c(C***)c(***)c1* Chemical compound Cc1c(*)c(*)c(C***)c(***)c1* 0.000 description 2
Claims (22)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00250194A EP1166798A1 (en) | 2000-06-23 | 2000-06-23 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use |
EP00250194.8 | 2000-06-23 | ||
EP00250214A EP1166799A1 (en) | 2000-06-28 | 2000-06-28 | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) |
EP00250214.4 | 2000-06-28 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2003100502A true RU2003100502A (en) | 2004-06-27 |
RU2292221C2 RU2292221C2 (en) | 2007-01-27 |
Family
ID=26072945
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2003100502/15A RU2292221C2 (en) | 2000-06-23 | 2001-06-20 | Combinations and compositions effecting on function of vegf/vegf receptor and angiopoietin/tie(ii) receptor systems and uses thereof |
Country Status (29)
Country | Link |
---|---|
US (2) | US20030055006A1 (en) |
EP (2) | EP1586333A2 (en) |
JP (1) | JP2003535910A (en) |
KR (2) | KR20080068151A (en) |
CN (1) | CN1479629A (en) |
AT (1) | ATE363291T1 (en) |
AU (1) | AU784231B2 (en) |
BG (1) | BG107396A (en) |
BR (1) | BR0111861A (en) |
CA (1) | CA2411236A1 (en) |
CY (1) | CY1107717T1 (en) |
CZ (1) | CZ2003187A3 (en) |
DE (1) | DE60128685T2 (en) |
DK (1) | DK1292335T3 (en) |
EE (1) | EE200200706A (en) |
ES (1) | ES2287152T3 (en) |
HR (1) | HRP20030041A2 (en) |
HU (1) | HUP0302779A3 (en) |
IL (1) | IL152794A0 (en) |
ME (1) | MEP13708A (en) |
MX (1) | MXPA02011897A (en) |
NO (1) | NO20026152L (en) |
NZ (1) | NZ536196A (en) |
PL (1) | PL359653A1 (en) |
PT (1) | PT1292335E (en) |
RS (1) | RS50249B (en) |
RU (1) | RU2292221C2 (en) |
SK (1) | SK542003A3 (en) |
WO (1) | WO2001097850A2 (en) |
Families Citing this family (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070026394A1 (en) | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
EP1289565B1 (en) | 2000-06-02 | 2015-04-22 | Bracco Suisse SA | Compounds for targeting endothelial cells |
US8263739B2 (en) | 2000-06-02 | 2012-09-11 | Bracco Suisse Sa | Compounds for targeting endothelial cells, compositions containing the same and methods for their use |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
AU2002314433A1 (en) * | 2001-07-02 | 2003-01-21 | Licentia Ltd. | Ephrin-tie receptor materials and methods |
US20050123925A1 (en) | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
AU2003207708A1 (en) * | 2002-02-20 | 2003-09-09 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of map kinase genes |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US8623822B2 (en) | 2002-03-01 | 2014-01-07 | Bracco Suisse Sa | KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy |
US7666979B2 (en) | 2002-03-01 | 2010-02-23 | Bracco International B.V. | Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same |
US7211240B2 (en) * | 2002-03-01 | 2007-05-01 | Bracco International B.V. | Multivalent constructs for therapeutic and diagnostic applications |
US20050250700A1 (en) * | 2002-03-01 | 2005-11-10 | Sato Aaron K | KDR and VEGF/KDR binding peptides |
US7261876B2 (en) | 2002-03-01 | 2007-08-28 | Bracco International Bv | Multivalent constructs for therapeutic and diagnostic applications |
US7985402B2 (en) | 2002-03-01 | 2011-07-26 | Bracco Suisse Sa | Targeting vector-phospholipid conjugates |
WO2004065621A1 (en) | 2002-03-01 | 2004-08-05 | Dyax Corp. | Kdr and vegf/kdr binding peptides and their use in diagnosis and therapy |
US7794693B2 (en) | 2002-03-01 | 2010-09-14 | Bracco International B.V. | Targeting vector-phospholipid conjugates |
AU2003243427A1 (en) * | 2002-06-04 | 2003-12-19 | Metabolex, Inc. | Methods of diagnosing and treating diabetes and insulin resistance |
GB0222276D0 (en) * | 2002-09-25 | 2002-10-30 | Inst Of Molecul & Cell Biology | Methods |
EP1603935A4 (en) | 2003-03-03 | 2007-03-21 | Dyax Corp | PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF |
CA2522730A1 (en) * | 2003-04-18 | 2004-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2 |
WO2005019267A2 (en) * | 2003-08-12 | 2005-03-03 | Dyax Corp. | Tie1-binding ligands |
US7871610B2 (en) * | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
EP1713915B1 (en) | 2004-02-10 | 2009-12-16 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING MULTIFUNCTIONAL SHORT INTERFERING NUCLEIC ACID (MULTIFUNCTIONAL siNA) |
US7422741B2 (en) | 2004-03-05 | 2008-09-09 | Vegenics Limited | VEGFR-3 fusion proteins |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
CN102641503A (en) * | 2004-07-20 | 2012-08-22 | 健泰科生物技术公司 | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
US8604185B2 (en) | 2004-07-20 | 2013-12-10 | Genentech, Inc. | Inhibitors of angiopoietin-like 4 protein, combinations, and their use |
US20060105663A1 (en) * | 2004-10-04 | 2006-05-18 | Stefan Greulich | Polymer assemblies with decorative surfaces |
US8986650B2 (en) | 2005-10-07 | 2015-03-24 | Guerbet | Complex folate-NOTA-Ga68 |
JP5368099B2 (en) | 2005-10-07 | 2013-12-18 | ゲルベ | A compound comprising a moiety for recognition of a biological target coupled to a signal moiety capable of complexing with gallium |
BRPI0619853A2 (en) | 2005-12-15 | 2016-08-23 | Astrazeneca Ab | combination, pharmaceutical composition, and methods of antagonizing biological activity, treating disease-related angiogenesis in a mammal, and treating cancer in a mammal |
EP1973950B1 (en) | 2006-01-05 | 2014-09-17 | Genentech, Inc. | Anti-ephb4 antibodies and methods using the same |
AR059066A1 (en) | 2006-01-27 | 2008-03-12 | Amgen Inc | COMBINATIONS OF THE ANGIOPOYETINE INHIBITOR -2 (ANG2) AND THE VASCULAR ENDOTELIAL GROWTH FACTOR INHIBITOR (VEGF) |
BRPI0709425A2 (en) * | 2006-03-29 | 2011-07-12 | Genentech Inc | use of a vegf antagonist and in vitro method to diagnose a resistant tumor |
ES2828739T3 (en) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Antibodies that bind to human protein tyrosine phosphatase beta (HPTP-beta) and their uses |
EP2029159A2 (en) * | 2006-06-06 | 2009-03-04 | Genentech, Inc. | Compositions and methods for modulating vascular development |
MX2008015541A (en) * | 2006-06-06 | 2008-12-18 | Genentech Inc | Anti-dll4 antibodies and methods using same. |
US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
US20080213253A1 (en) * | 2007-01-12 | 2008-09-04 | Dyax Corp. | Combination therapy for the treatment of cancer |
EP2125013A4 (en) * | 2007-01-26 | 2010-04-07 | Bioinvent Int Ab | Dll4 signaling inhibitors and uses thereof |
US10259860B2 (en) * | 2007-02-27 | 2019-04-16 | Aprogen Inc. | Fusion proteins binding to VEGF and angiopoietin |
US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
PE20090983A1 (en) * | 2007-11-09 | 2009-08-13 | Genentech Inc | COMPOSITIONS AND METHODS OF USE OF KINASE-1 SIMILAR TO THE ACTIVIN RECEPTOR |
TWI468417B (en) * | 2007-11-30 | 2015-01-11 | Genentech Inc | Anti-vegf antibodies |
CA2727792C (en) | 2008-03-14 | 2017-07-25 | Obschestvo S Ogranichennoi Otvetstvennostyu "Initium-Pharm" | Antitumoral terpenoid pharmaceutical composition abisilin exhibiting angiogenesis-inhibiting action |
BRPI0912927A2 (en) * | 2008-08-29 | 2019-10-01 | Genentech Inc | "Method of detecting a vegf independent tumor in an individual and method of treating a vegf independent tumor in an individual" |
TWI572359B (en) | 2008-10-14 | 2017-03-01 | 建南德克公司 | Immunoglobulin variants and uses thereof |
AU2009313551B2 (en) | 2008-11-07 | 2015-12-17 | Fabrus Llc | Anti-DLL4 antibodies and uses thereof |
FR2942227B1 (en) | 2009-02-13 | 2011-04-15 | Guerbet Sa | USE OF BUFFERS FOR RADIONUCLEID COMPLEXATION |
BRPI1006897A2 (en) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compounds, compositions and methods for preventing cancer cell metastasis. |
KR20120089253A (en) * | 2009-07-31 | 2012-08-09 | 제넨테크, 인크. | Inhibition of tumor metastasis using bv8- or g-csf-antagonists |
WO2011056494A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations |
WO2011056502A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Bone morphogenetic protein receptor type ii compositions and methods of use |
WO2011056497A1 (en) | 2009-10-26 | 2011-05-12 | Genentech, Inc. | Activin receptor type iib compositions and methods of use |
EP2496600A1 (en) | 2009-11-04 | 2012-09-12 | Fabrus LLC | Methods for affinity maturation-based antibody optimization |
TWI505836B (en) | 2009-12-11 | 2015-11-01 | Genentech Inc | Anti-vegf-c antibodies and methods using same |
SG181905A1 (en) | 2009-12-23 | 2012-07-30 | Genentech Inc | Anti-bv8 antibodies and uses thereof |
EP3327125B1 (en) | 2010-10-29 | 2020-08-05 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina) |
KR20130124513A (en) | 2010-11-15 | 2013-11-14 | 파이브 프라임 테라퓨틱스, 인크. | Treatment of cancer with elevated dosages of soluble fgfr1 fusion proteins |
FR2968999B1 (en) | 2010-12-20 | 2013-01-04 | Guerbet Sa | CHELATE NANOEMULSION FOR MRI |
WO2012092539A2 (en) | 2010-12-31 | 2012-07-05 | Takeda Pharmaceutical Company Limited | Antibodies to dll4 and uses thereof |
WO2012145539A1 (en) | 2011-04-20 | 2012-10-26 | Acceleron Pharma, Inc. | Endoglin polypeptides and uses thereof |
CN102250248A (en) * | 2011-06-15 | 2011-11-23 | 常州亚当生物技术有限公司 | Anti-VEGF/ANG2 bispecific antibody, and application thereof |
WO2013025944A1 (en) | 2011-08-17 | 2013-02-21 | Genentech, Inc. | Inhibition of angiogenesis in refractory tumors |
JP6333174B2 (en) | 2011-08-19 | 2018-05-30 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Anti-TIE2 antibody and use thereof |
US10316105B2 (en) | 2011-08-19 | 2019-06-11 | Regeneron Pharmaceuticals, Inc. | Anti-TIE2 antibodies and uses thereof |
FR2980364B1 (en) | 2011-09-26 | 2018-08-31 | Guerbet | NANOEMULSIONS AND THEIR USE AS CONTRAST AGENTS |
EP2766044B1 (en) | 2011-10-13 | 2019-12-11 | Aerpio Therapeutics, Inc. | Treatment of ocular disease |
CN104039351A (en) | 2011-10-13 | 2014-09-10 | 阿尔皮奥治疗学股份有限公司 | Methods for treating vascular leak syndrome and cancer |
WO2013082511A1 (en) | 2011-12-02 | 2013-06-06 | Genentech, Inc. | Methods for overcoming tumor resistance to vegf antagonists |
FR3001154B1 (en) | 2013-01-23 | 2015-06-26 | Guerbet Sa | MAGNETO-EMULSION VECTORIZED |
US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
AU2014339898B2 (en) | 2013-10-25 | 2020-07-23 | Acceleron Pharma, Inc. | Endoglin peptides to treat fibrotic diseases |
EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
KR20190031246A (en) | 2016-07-20 | 2019-03-25 | 에르피오 세러퓨틱스 인코포레이티드 | Humanized monoclonal antibody targeting VE-PTP (HPTP-beta) |
MA46036A (en) | 2016-08-23 | 2019-07-03 | Medimmune Ltd | ANTI-VEGF-A AND ANTI-ANG2 ANTIBODIES AND THEIR USES |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4950519A1 (en) * | 1997-02-13 | 2000-09-01 | Novartis Ag | PHTHALAZINES, PHARMACEUTICAL PREPARATIONS THAT UNDERSTAND THEM AND THE PROCESS FOR THEIR PREPARATION |
US6703020B1 (en) * | 1999-04-28 | 2004-03-09 | Board Of Regents, The University Of Texas System | Antibody conjugate methods for selectively inhibiting VEGF |
-
2001
- 2001-06-20 ES ES01965012T patent/ES2287152T3/en not_active Expired - Lifetime
- 2001-06-20 NZ NZ536196A patent/NZ536196A/en unknown
- 2001-06-20 DK DK01965012T patent/DK1292335T3/en active
- 2001-06-20 IL IL15279401A patent/IL152794A0/en unknown
- 2001-06-20 AU AU85766/01A patent/AU784231B2/en not_active Ceased
- 2001-06-20 EP EP05090011A patent/EP1586333A2/en not_active Withdrawn
- 2001-06-20 MX MXPA02011897A patent/MXPA02011897A/en active IP Right Grant
- 2001-06-20 DE DE60128685T patent/DE60128685T2/en not_active Expired - Fee Related
- 2001-06-20 SK SK54-2003A patent/SK542003A3/en unknown
- 2001-06-20 EE EEP200200706A patent/EE200200706A/en unknown
- 2001-06-20 WO PCT/EP2001/006976 patent/WO2001097850A2/en active IP Right Grant
- 2001-06-20 CA CA002411236A patent/CA2411236A1/en not_active Abandoned
- 2001-06-20 BR BR0111861-7A patent/BR0111861A/en not_active IP Right Cessation
- 2001-06-20 KR KR1020087016915A patent/KR20080068151A/en not_active Application Discontinuation
- 2001-06-20 HU HU0302779A patent/HUP0302779A3/en unknown
- 2001-06-20 EP EP01965012A patent/EP1292335B1/en not_active Expired - Lifetime
- 2001-06-20 PT PT01965012T patent/PT1292335E/en unknown
- 2001-06-20 PL PL01359653A patent/PL359653A1/en unknown
- 2001-06-20 KR KR1020027017482A patent/KR20030036238A/en not_active Application Discontinuation
- 2001-06-20 CZ CZ2003187A patent/CZ2003187A3/en unknown
- 2001-06-20 CN CNA018115837A patent/CN1479629A/en active Pending
- 2001-06-20 ME MEP-137/08A patent/MEP13708A/en unknown
- 2001-06-20 JP JP2002503334A patent/JP2003535910A/en active Pending
- 2001-06-20 RU RU2003100502/15A patent/RU2292221C2/en not_active IP Right Cessation
- 2001-06-20 RS YU97202A patent/RS50249B/en unknown
- 2001-06-20 AT AT01965012T patent/ATE363291T1/en not_active IP Right Cessation
- 2001-06-25 US US09/887,527 patent/US20030055006A1/en not_active Abandoned
-
2002
- 2002-12-17 BG BG107396A patent/BG107396A/en unknown
- 2002-12-20 NO NO20026152A patent/NO20026152L/en not_active Application Discontinuation
-
2003
- 2003-01-23 HR HR20030041A patent/HRP20030041A2/en not_active Application Discontinuation
-
2004
- 2004-03-10 US US10/796,174 patent/US20040147449A1/en not_active Abandoned
-
2007
- 2007-08-14 CY CY20071101085T patent/CY1107717T1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2003100502A (en) | COMBINATIONS AND COMPOSITIONS THAT HAVE EFFECT ON THE FUNCTION OF VEGF SYSTEMS / VEGF RECEPTOR AND ANGIOPOETIN / TIE (II) RECEPTOR, AND THEIR APPLICATION | |
RU2292221C2 (en) | Combinations and compositions effecting on function of vegf/vegf receptor and angiopoietin/tie(ii) receptor systems and uses thereof | |
Zhan et al. | From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1/PD-L1 pathway | |
US7422741B2 (en) | VEGFR-3 fusion proteins | |
JP2020532529A (en) | Cyclic dinucleotide as an anticancer drug | |
KR102088469B1 (en) | Combination therapy of a mek inhibitor and igf1r inhibitor | |
RO123115B1 (en) | Selective antibody for tumor necrosis factor-related apoptosis-inducing ligand receptor | |
CN117752784A (en) | Dosing regimen of a combination of a Wnt inhibitor and an anti-PD-1 antibody molecule | |
AU2018268420B2 (en) | Compositions comprising naphthyridine derivatives and aluminium adjuvant for use in treating solid tumors | |
EP4142798A1 (en) | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention in brain tumors | |
KR20180100652A (en) | A combination of a chromene compound and a second activator | |
JP7080234B2 (en) | Benzamide and active compound compositions and methods of use | |
EP1166798A1 (en) | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/ Tie receptor function and their use | |
EP1166799A1 (en) | Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/Tie receptor function and their use (II) | |
EP3125901B1 (en) | Derivatives of cephalosporin for treating cancer | |
WO2013085973A1 (en) | Treatment for angiogenic disorders | |
JP7506079B2 (en) | Heterocyclic nlrp3 modulators for use in the treatment of cancer - Patents.com | |
TWI804339B (en) | Methods of increasing cell phagocytosis | |
WO2023232022A1 (en) | Recombinant fusion protein targeting pd-l1 and vegf, and preparation and use thereof | |
JP2023510323A (en) | NLRP3 modulator | |
TW202210071A (en) | Combination of small molecule inhibitor of pd-1/pd-l1 interaction and anti-pd-1 antibody for treatment of cancer | |
JP2011231023A (en) | Infiltration inhibitor |